Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Gains from Investment Securities (2017 - 2025)

Historic Gains from Investment Securities for Cue Biopharma (CUE) over the last 9 years, with Q3 2025 value amounting to $13.8 million.

  • Cue Biopharma's Gains from Investment Securities rose 2983.13% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.8 million, marking a year-over-year increase of 2983.13%. This contributed to the annual value of $10.5 million for FY2024, which is 3975.5% up from last year.
  • Per Cue Biopharma's latest filing, its Gains from Investment Securities stood at $13.8 million for Q3 2025, which was up 2983.13% from $10.9 million recorded in Q2 2025.
  • Cue Biopharma's 5-year Gains from Investment Securities high stood at $13.8 million for Q3 2025, and its period low was $816000.0 during Q1 2022.
  • Its 5-year average for Gains from Investment Securities is $6.8 million, with a median of $7.1 million in 2023.
  • Per our database at Business Quant, Cue Biopharma's Gains from Investment Securities soared by 279500.0% in 2021 and then tumbled by 604.49% in 2022.
  • Over the past 5 years, Cue Biopharma's Gains from Investment Securities (Quarter) stood at $1.0 million in 2021, then surged by 63.35% to $1.7 million in 2022, then soared by 347.52% to $7.5 million in 2023, then surged by 39.61% to $10.5 million in 2024, then soared by 31.57% to $13.8 million in 2025.
  • Its last three reported values are $13.8 million in Q3 2025, $10.9 million for Q2 2025, and $12.3 million during Q1 2025.